Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSNeo-DC1.1 plus temozolomide in newly diagnosed glioblastoma (post-surgery, post-chemoradiation)
CTR20260143Phase 2Terminated
- Sponsor
- Sino-Cell Biotech
- Start
- Jan 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ZSNeo-DC1.1 in glioblastoma (GBM), sponsored by Sino-Cell Biotech. Started Jan 2026; status: terminated.
02
Drugs
ZSNeo-DC1.1
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20260143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260143.